Generic Name: ziftomenib

Therapeutic Class or Brand Name: Komzifti

Applicable Drugs: N/A

Preferred: N/A

Non-preferred: N/A

Date of Origin: 6/1/2026

Date Last Reviewed / Revised: N/A

PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I to V are met.)

I. Documentation of the following FDA-approved diagnosis and must meet all criteria listed under the applicable diagnosis:

FDA-Approved Indication(s)

A. Acute Myeloid Leukemia

i. Documentation of nucleophosmin 1 (NPM1) mutation

ii. Documentation of relapsed or refractory disease

iii. Documentation or attestation by physician that there are no satisfactory alternative treatment options.

II. Minimum age requirement: 18 years old or older.

III. Treatment must be prescribed by or in consultation with an oncologist or hematologist.

IV. Request is for a medication with the appropriate FDA labeling, or its use is supported by current National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1 or 2A.

V. Refer to the plan document for the list of preferred products. If the requested agent is not listed as a preferred product, must have documented treatment failure or contraindication to the preferred product(s).

EXCLUSION CRITERIA

- N/A

OTHER CRITERIA

- N/A

QUANTITY / DAYS SUPPLY RESTRICTIONS

- Quantity limited to #90 capsules per 30 days

Approval Length

- **Authorization:** 6 months
- **Re-Authorization:** 6 months. An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and does not show evidence of progressive disease.

Appendix

N/A

References

1. Komzifti. Prescribing Information. Kura Oncology, Inc. 2025. Accessed March 5, 2026. www.accessdata.fda.gov/drugsatfda_docs/label/2025/220305s000lbl.pdf
2. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 3.2026. Updated November 24, 2025. Accessed March 6, 2026. www.nccn.org/professionals/physician_gls_pdf/aml.pdf